External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis. [PDF]
Cost Eff Resour AllocCampello CRS, da Costa MGS, Pinto M.
europepmc +1 more source
Blocking Sphingosine 1-phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease. [PDF]
J Cell PhysiolSkafi N +16 more
europepmc +1 more source
Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis. [PDF]
Afr J Lab MedKamal DT +4 more
europepmc +1 more source
Correction to "Blocking Sphingosine 1-phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease". [PDF]
J Cell Physioleuropepmc +1 more source
Clinical Pharmacokinetics of Fingolimod
Clinical Pharmacokinetics, 2012 Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compounds and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).
John M Kovarik +2 more
exaly +2 more sources
Delayed fingolimod-associated asystole
Multiple Sclerosis Journal, 2011 Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS).
Patricio S Espinosa, Joseph R Berger
exaly +2 more sources
Related searches: